{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:54:33Z","timestamp":1790996073038,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04966-x","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:18:11Z","timestamp":1790993891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous infusion of granulocyte colony-stimulating factor is associated with an advantage in neutrophil recovery in pediatric oncologic disorders"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0003-5153","authenticated-orcid":false,"given":"Yi-Lun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Yen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hsiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tang-Her","family":"Jaing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"5","key":"4966_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052941","volume":"12","author":"E Musta","year":"2022","unstructured":"Musta E, van Geloven N, Anninga J, Gelderblom H, Fiocco M (2022) Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial. BMJ Open 12(5):e052941","journal-title":"BMJ Open"},{"issue":"2","key":"4966_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/MPH.0000000000001384","volume":"41","author":"S Ash","year":"2019","unstructured":"Ash S, Yaniv I, Toledano H, Stein J, Kollender Y, Fenig E et al (2019) Improved Outcome in Local Ewing Sarcoma With an Intensified Pilot Treatment Protocol SCMCIE 94. J Pediatr Hematol Oncol 41(2):105\u2013111","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"4966_CR3","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1097\/MPH.0000000000001820","volume":"42","author":"K Yamasaki","year":"2020","unstructured":"Yamasaki K, Okada K, Soejima T, Kosaka Y, Nagashima T, Hara J (2020) Outcomes of Local Radiation and Intensified Combined Intrathecal Methotrexate and High-dose Chemotherapy for Intracranial Germ Cell Tumors. J Pediatr Hematol Oncol 42(7):e551\u2013e557","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"4966_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/pbc.25824","volume":"63","author":"S Sunami","year":"2016","unstructured":"Sunami S, Sekimizu M, Takimoto T, Mori T, Mitsui T, Fukano R et al (2016) Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma: A Report From the Japanese Pediatric Leukemia\/Lymphoma Study Group ALB-NHL03 Study. Pediatr Blood Cancer 63(3):451\u2013457","journal-title":"Pediatr Blood Cancer"},{"issue":"14","key":"4966_CR5","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","volume":"28","author":"G Tallen","year":"2010","unstructured":"Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A et al (2010) Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 28(14):2339\u20132347","journal-title":"J Clin Oncol"},{"issue":"5","key":"4966_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","volume":"32","author":"T Hilal","year":"2018","unstructured":"Hilal T, Gea-Banacloche JC, Leis JF (2018) Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Rev 32(5):387\u2013399","journal-title":"Blood Rev"},{"key":"4966_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100738","volume":"46","author":"A Ohmoto","year":"2021","unstructured":"Ohmoto A, Fuji S (2021) Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL. Blood Rev 46:100738","journal-title":"Blood Rev"},{"issue":"2","key":"4966_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.idc.2019.01.001","volume":"33","author":"S Atkins","year":"2019","unstructured":"Atkins S, He F (2019) Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies. Infect Dis Clin North Am 33(2):289\u2013309","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"4966_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12985-020-01302-4","volume":"17","author":"I Handous","year":"2020","unstructured":"Handous I, Achour B, Marzouk M, Rouis S, Hazgui O, Brini I et al (2020) Co-infections of human herpesviruses (CMV, HHV-6, HHV-7 and EBV) in non-transplant acute leukemia patients undergoing chemotherapy. Virol J 17(1):37","journal-title":"Virol J"},{"issue":"3","key":"4966_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/vco.12406","volume":"16","author":"JL Bisson","year":"2018","unstructured":"Bisson JL, Argyle DJ, Argyle SA (2018) Antibiotic prophylaxis in veterinary cancer chemotherapy: A review and recommendations. Vet Comp Oncol 16(3):301\u2013310","journal-title":"Vet Comp Oncol"},{"issue":"3","key":"4966_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11739-018-02015-x","volume":"14","author":"YJ Kim","year":"2019","unstructured":"Kim YJ, Jung SM, Kang J, Ryoo SM, Sohn CH, Seo DW et al (2019) Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia. Intern Emerg Med 14(3):433\u2013440","journal-title":"Intern Emerg Med"},{"issue":"1","key":"4966_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08447-x","volume":"23","author":"R Wang","year":"2023","unstructured":"Wang R, Jiang A, Zhang R, Shi C, Ding Q, Liu S et al (2023) Establishment of a risk classifier to predict the in-hospital death risk of nosocomial fungal infections in cancer patients. BMC Infect Dis 23(1):472","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4966_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12941-020-00395-7","volume":"19","author":"AM Jiang","year":"2020","unstructured":"Jiang AM, Liu N, Zhao R, Zheng HR, Chen X, Fan CX et al (2020) Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis. Ann Clin Microbiol Antimicrob 19(1):53","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"4966_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000046557","volume":"105","author":"G Morstyn","year":"2001","unstructured":"Morstyn G, Foote MA, Walker T, Molineux G (2001) Filgrastim (r-metHuG-CSF) in the 21st century: SD\/01. Acta Haematol 105(3):151\u2013155","journal-title":"Acta Haematol"},{"issue":"5","key":"4966_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50(5):295\u2013306","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"4966_CR16","first-page":"19","volume":"118","author":"DS Aschenbrenner","year":"2018","unstructured":"Aschenbrenner DS (2018) First Pegfilgrastim Biosimilar Approved. Am J Nurs 118(10):19\u201320","journal-title":"Am J Nurs"},{"key":"4966_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/0-306-47452-2_7","volume":"9","author":"AC Herman","year":"1996","unstructured":"Herman AC, Boone TC, Lu HS (1996) Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor. Pharm Biotechnol 9:303\u2013328","journal-title":"Pharm Biotechnol"},{"issue":"6","key":"4966_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0151","volume":"1","author":"D Metcalf","year":"2013","unstructured":"Metcalf D (2013) The colony-stimulating factors and cancer. Cancer Immunol Res 1(6):351\u2013356","journal-title":"Cancer Immunol Res"},{"issue":"28","key":"4966_CR19","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"1","key":"4966_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"issue":"3","key":"4966_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ajh.23622","volume":"89","author":"M Paul","year":"2014","unstructured":"Paul M, Ram R, Kugler E, Farbman L, Peck A, Leibovici L et al (2014) Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. Am J Hematol 89(3):243\u2013248","journal-title":"Am J Hematol"},{"issue":"4","key":"4966_CR22","first-page":"273","volume":"19","author":"CS Rosenfeld","year":"1991","unstructured":"Rosenfeld CS, Sulecki M, Evans C, Shadduck RK (1991) Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol 19(4):273\u2013277","journal-title":"Exp Hematol"},{"issue":"2","key":"4966_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.arcped.2022.11.004","volume":"30","author":"A Eroglu","year":"2023","unstructured":"Eroglu A, Hazar V (2023) Evaluation of health-related quality of life in childhood cancer survivors. Arch Pediatr 30(2):89\u201392","journal-title":"Arch Pediatr"},{"key":"4966_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pedn.2018.11.009","volume":"44","author":"H Shin","year":"2019","unstructured":"Shin H, Bartlett R, De Gagne JC (2019) Health-related quality of life among survivors of cancer in adolescence: an integrative literature review. J Pediatr Nurs 44:97\u2013106","journal-title":"J Pediatr Nurs"},{"issue":"5","key":"4966_CR25","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00520-020-05869-0","volume":"29","author":"JT Bosman","year":"2021","unstructured":"Bosman JT, Bood ZM, Scherer-Rath M, Dorr H, Christophe N, Sprangers MAG et al (2021) The effects of art therapy on anxiety, depression, and quality of life in adults with cancer: a systematic literature review. Support Care Cancer 29(5):2289\u20132298","journal-title":"Support Care Cancer"},{"issue":"11","key":"4966_CR26","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.31557\/APJCP.2022.23.11.3905","volume":"23","author":"GG Gan","year":"2022","unstructured":"Gan GG, Tey KWF, Mat S, Saad M, Bee PC, Abdul Malik R et al (2022) Quality of Life of Family Caregivers of Cancer Patients in a Developing Nation. Asian Pac J Cancer Prev 23(11):3905\u20133914","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"4966_CR27","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1038\/bcj.2015.29","volume":"5","author":"P Allart-Vorelli","year":"2015","unstructured":"Allart-Vorelli P, Porro B, Baguet F, Michel A, Cousson-Gelie F (2015) Haematological cancer and quality of life: a systematic literature review. Blood Cancer J 5(4):e305","journal-title":"Blood Cancer J"},{"key":"4966_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17196938","author":"A Lewandowska","year":"2020","unstructured":"Lewandowska A, Rudzki G, Lewandowski T, Prochnicki M, Rudzki S, Laskowska B et al (2020) Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph17196938","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"4966_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/17474086.2022.2093712","volume":"15","author":"K Campbell","year":"2022","unstructured":"Campbell K, Chadha N, Dimri S, Wang W, Li E (2022) G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. Expert Rev Hematol 15(7):619\u2013633","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"4966_CR30","doi-asserted-by":"publisher","first-page":"945","DOI":"10.6004\/jnccn.2023.7044","volume":"21","author":"DW Blayney","year":"2023","unstructured":"Blayney DW, Kuderer NM, Cummings Joyner AK, Jarvis J, Nunag D, Wells J et al (2023) Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy. J Natl Compr Canc Netw 21(9):945\u2013950 e916","journal-title":"J Natl Compr Canc Netw"},{"issue":"50","key":"4966_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002044","volume":"94","author":"B Mathias","year":"2015","unstructured":"Mathias B, Szpila BE, Moore FA, Efron PA, Moldawer LL (2015) A review of GM-CSF therapy in sepsis. Medicine (Baltimore) 94(50):e2044","journal-title":"Medicine (Baltimore)"},{"issue":"34","key":"4966_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030155","volume":"101","author":"NK Kim","year":"2022","unstructured":"Kim NK, Suh DH, Kim K, No JH, Kim YB (2022) Maximum daily dose of G-CSF is critical for preventing recurrence of febrile neutropenia in patients with gynecologic cancer: a case-control study. Medicine (Baltimore) 101(34):e30155","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"4966_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s11912-022-01192-5","volume":"24","author":"S Villeneuve","year":"2022","unstructured":"Villeneuve S, Aftandilian C (2022) Neutropenia and Infection Prophylaxis in Childhood Cancer. Curr Oncol Rep 24(6):671\u2013686","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"4966_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1182\/hematology.2020000098","volume":"2020","author":"C Logan","year":"2020","unstructured":"Logan C, Koura D, Taplitz R (2020) Updates in infection risk and management in acute leukemia. Hematology Am Soc Hematol Educ Program 2020(1):135\u2013139","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"4966_CR35","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1200\/JCO.22.02224","volume":"41","author":"T Lehrnbecher","year":"2023","unstructured":"Lehrnbecher T, Robinson PD, Ammann RA, Fisher B, Patel P, Phillips R et al (2023) Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update. J Clin Oncol 41(9):1774\u20131785","journal-title":"J Clin Oncol"},{"issue":"3","key":"4966_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.paed.2019.12.002","volume":"30","author":"K Davis","year":"2020","unstructured":"Davis K, Wilson S (2020) Febrile neutropenia in paediatric oncology. Paediatr Child Health (Oxford) 30(3):93\u201397","journal-title":"Paediatr Child Health (Oxford)"},{"issue":"6","key":"4966_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13701","volume":"23","author":"VJ Gow-Lee","year":"2021","unstructured":"Gow-Lee VJ, Moyers JT, Rogstad DK (2021) Fatal recurrent disseminated Lomentospora prolificans infection during autologous hematopoietic stem cell transplantation: a case report and review, and discussion on the importance of prolonged neutropenia. Transpl Infect Dis 23(6):e13701","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"4966_CR38","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(20)30725-7","volume":"22","author":"T Lehrnbecher","year":"2021","unstructured":"Lehrnbecher T, Averbuch D, Castagnola E, Cesaro S, Ammann RA, Garcia-Vidal C et al (2021) 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol 22(6):e270\u2013e280","journal-title":"Lancet Oncol"},{"issue":"6","key":"4966_CR39","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/ejh.13162","volume":"101","author":"C Calitri","year":"2018","unstructured":"Calitri C, Ruberto E, Castagnola E (2018) Antibiotic prophylaxis in neutropenic children with acute leukemia: Do the presently available data really support this practice? Eur J Haematol 101(6):721\u2013727","journal-title":"Eur J Haematol"},{"issue":"27","key":"4966_CR40","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.20.00158","volume":"38","author":"T Lehrnbecher","year":"2020","unstructured":"Lehrnbecher T, Fisher BT, Phillips B, Beauchemin M, Carlesse F, Castagnola E et al (2020) Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol 38(27):3205\u20133216","journal-title":"J Clin Oncol"},{"issue":"4","key":"4966_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.htct.2022.09.1279","volume":"45","author":"MC Dufrayer","year":"2023","unstructured":"Dufrayer MC, Monteiro YMC, Carlesse F, Motta F, Daudt LE, Michalowski MB (2023) Antibiotic prophylaxis in acute childhood leukemia: What is known so far? Hematol Transfus Cell Ther 45(4):473\u2013482","journal-title":"Hematol Transfus Cell Ther"},{"issue":"1","key":"4966_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","volume":"89","author":"M Lambertini","year":"2014","unstructured":"Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2014) The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 89(1):112\u2013128","journal-title":"Crit Rev Oncol Hematol"},{"key":"4966_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103193","volume":"157","author":"P Lapidari","year":"2021","unstructured":"Lapidari P, Vaz-Luis I, Di Meglio A (2021) Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: a systematic review. Crit Rev Oncol Hematol 157:103193","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4966_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MOH.0b013e328319913c","volume":"16","author":"P Anderlini","year":"2009","unstructured":"Anderlini P (2009) Effects and safety of granulocyte colony-stimulating factor in healthy volunteers. Curr Opin Hematol 16(1):35\u201340","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"4966_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4103\/ijc.IJC_982_19","volume":"59","author":"U Deb","year":"2022","unstructured":"Deb U, Mukhopadhyay S, Banerjee S, Biswas S (2022) Safety profile of G-CSF in chemotherapy-induced neutropenia: A prospective observational study in Eastern India. Indian J Cancer 59(4):493\u2013498","journal-title":"Indian J Cancer"},{"issue":"4","key":"4966_CR46","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","volume":"29","author":"ZD Crees","year":"2023","unstructured":"Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I et al (2023) Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med 29(4):869\u2013879","journal-title":"Nat Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04966-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04966-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04966-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:18:12Z","timestamp":1790993892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04966-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4966"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04966-x","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval, as well as consent to participate and publish, were obtained through formal informed consent from the participants\u2019 legal guardians. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Chang Gung Memorial Hospital (IRB identifier: 202301323A3).","order":2,"name":"Ethics","label":"Ethics, Consent to Participate, and Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}